At ESMO, Professor Masatoshi Kudo from Kindai University shared results from a matching-adjusted indirect comparison of nivolumab + ipilimumab (CheckMate 9DW) versus durvalumab + tremelimumab (HIMALAYA) and atezolizumab + bevacizumab (IMbrave150) in advanced HCC.
NIVO+IPI showed numerically better early PFS, OS, and response rates. Prof. Kudo emphasized the unique response pattern of anti-CTLA-4 therapies and highlighted the potential of early biomarkers like AFP and DCP to guide treatment decisions.
